Drug Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

Aptamer Extends Agreement for Drug Delivery Vehicles

November 07, 2024

A genetic medicines customer has selected the company’s binders for commercial development of the customer’s product.

Accelerating Discovery and Development with Advances in High-Throughput Screening

November 07, 2024

Automation, miniaturization, and new software algorithms are improving throughput and accuracy.

Synaffix, a Lonza Company, Collaborates with BigHat Biosciences on ADCs Designed Using Machine Learning

November 07, 2024

Synaffix, a Lonza company, has licensed its ADC technology to BigHat Biosciences to be combined with the latter's ML design platform to develop new ADCs

FDA Rare Disease Innovation Moves Forward

November 01, 2024

CDER Director Patrizia Cavazzoni and CBER Director Peter Marks provided an update on the rare disease innovation hub in a new FDA Voices blog post.

Lilly and ViaNautis Bio Partner on Development of Novel Therapeutics Delivering Genetic Cargo

October 31, 2024

The partnership will use ViaNautis’ proprietary polyNaut technology platform to develop genetic medicines that can precisely target tissue types.

Webcasts

Focusing on Solid Dosage Trends and Demand

October 30, 2024

Webinar Date/Time: Fri, Nov 22, 2024 11:00 AM EST

Novartis and Monte Rosa Therapeutics Form $2.1 Billion Global License Agreement for MGD-based Therapeutics

October 29, 2024

The collaboration aims to advance clinical development of a Phase I drug candidate, MRT-6160, and to explore other therapeutic opportunities across multiple indications.

Webcasts